Form 4: ResMed CEO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
ResMed Inc.'s Chairman and CEO, Michael J. Farrell, exercised options and sold 4,991 shares of common stock on January 7, 2026, under a pre-arranged 10b5-1 trading plan.
Summary
- Michael J. Farrell, Chairman and CEO of ResMed Inc., engaged in a transaction on January 7, 2026.
- The transaction involved the exercise of 4,991 derivative securities (options) at an exercise price of $146.34 per share.
- Concurrently, 4,991 shares of ResMed Common Stock were disposed of at a weighted average sale price of $248.4603 per share, with individual trades ranging from $246.801 to $249.969.
- These transactions were conducted pursuant to a Rule 10b5-1 plan adopted on October 31, 2024.
- Following these transactions, Michael J. Farrell directly beneficially owns 466,223 shares of ResMed Common Stock and indirectly owns 2,090 shares through the Lisette and Michael Farrell Family Trust.
- He also beneficially owns 49,912 derivative securities (options).
Sentiment
Score: 5
Explanation: The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, indicating a planned liquidity event rather than a reactive move based on new information. The executive profited from option exercise, which is a common aspect of executive compensation.
Positives
- The executive realized a significant profit from exercising options at $146.34 and selling the shares at a weighted average price of $248.4603.
- The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned liquidity event rather than a reactive sale based on new, non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.
Negatives
- An executive selling shares, even under a 10b5-1 plan, can sometimes be perceived with slight caution by some investors, although it is a common practice for executive compensation and liquidity management.
Risks
- No specific risks related to the company's operations or financial health were disclosed in this Form 4 filing, as it primarily reports an insider transaction.
Future Outlook
No forward-looking statements or guidance regarding the company's future performance or strategic direction were provided in this Form 4 filing.
Management Comments
- No specific management comments or notable quotes were provided beyond the signature acknowledging the filing by Michael J. Farrell, Chairman and CEO.
Industry Context
This Form 4 filing details an individual executive's stock transaction and does not provide information directly related to broader industry trends, competitive landscape, or the company's operational performance within its sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | The transaction was executed under a Rule 10b5-1 plan adopted on October 31, 2024, which is a corporate governance mechanism designed to allow insiders to sell shares without concerns about insider trading by pre-scheduling transactions. | 10/31/2024 | Enhances transparency and provides an affirmative defense against insider trading allegations for pre-planned sales. |
Related Party Transactions
- Michael J. Farrell's indirect beneficial ownership of 2,090 shares through the Lisette and Michael Farrell Family Trust represents a related party disclosure.
Stakeholder Impact
- Shareholders: May note the executive's sale, but the pre-arranged 10b5-1 plan typically mitigates concerns about opportunistic selling, suggesting a planned liquidity event rather than a signal about company performance.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Next Steps
- No specific future actions, events, or milestones for the company were mentioned in this Form 4 filing.
Key Dates
| Date | Description |
|---|---|
| 11/11/2020 | Date options first became exercisable (options vest 1/3 per year). |
| 10/31/2024 | Date the Rule 10b5-1 plan was adopted. |
| 01/07/2026 | Date of the reported option exercise and stock sale transactions. |
| 01/08/2026 | Date the Form 4 was signed by Michael J. Farrell. |
| 11/21/2026 | Expiration date of the derivative securities (options). |
Recommendation
holdThe Form 4 reports a routine insider transaction where the CEO exercised options and sold shares under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a change in company fundamentals or future prospects and does not provide a basis for altering an investment recommendation. Investors should continue to evaluate ResMed based on its operational performance, financial results, and market outlook.
Keywords
ResMed, RMD, Michael J. Farrell, Insider Trading, Form 4, Stock Sale, Option Exercise, 10b5-1 Plan, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.